Moody National Bank Trust Division’s GSK GSK Stock Holding History

Moody National Bank Trust Division’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$495K	Buy	10,279 +52	+0.5%	+$2.65K	0.04%	347
2026 Q2	$536K	Sell	10,227 -11	-0.1%	-$582	0.04%	336
2026 Q1	$565K	Sell	10,238 -802	-7%	-$43.5K	0.05%	323
2025 Q4	$541K	Buy	11,040 +705	+7%	+$32.9K	0.05%	332
2025 Q3	$446K	Sell	10,335 -1,191	-10%	-$46.5K	0.04%	360
2025 Q2	$443K	Buy	11,526 +461	+4%	+$17.6K	0.04%	353
2025 Q1	$429K	Buy	11,065 +473	+4%	+$17.3K	0.04%	361
2024 Q4	$358K	Sell	10,592 -13	-0.1%	-$468	0.04%	383
2024 Q3	$434K	Buy	10,605 +949	+10%	+$38.8K	0.05%	361
2024 Q2	$372K	Sell	9,656 -400	-4%	-$16.8K	0.03%	353
2024 Q1	$431K	Sell	10,056 -2,108	-17%	-$86.9K	0.03%	348
2023 Q4	$451K	Sell	12,164 -7,101	-37%	-$255K	0.04%	351
2023 Q3	$698K	Hold	19,265	–	–	0.05%	307
2023 Q2	$687K	Buy	19,265 +380	+2%	+$13.6K	0.05%	297
2023 Q1	$672K	Buy	18,885 +203	+1%	+$7.1K	0.06%	281
2022 Q4	$656K	Buy	+18,682	New	+$622K	0.06%	275
2022 Q3	–	Sell	-8,985	Closed	-$489K	–	586
2022 Q2	$489K	Sell	8,985 -2,786	-24%	-$154K	0.05%	291
2022 Q1	$641K	Sell	11,771 -58	-0.5%	-$3.15K	0.02%	256
2021 Q4	$652K	Sell	11,829 -32,568	-73%	-$1.69M	0.02%	257
2021 Q3	$2.12M	Sell	44,397 -80	-0.2%	-$4.02K	0.03%	226
2021 Q2	$2.21M	Buy	44,477 +476	+1%	+$22.9K	0.05%	228
2021 Q1	$1.96M	Buy	44,001 +203	+0.5%	+$9.21K	0.05%	229
2020 Q4	$2.02M	Buy	43,798 +982	+2%	+$45.1K	0.05%	214
2020 Q3	$2.01M	Hold	42,816	–	–	0.06%	200
2020 Q2	$2.18M	Buy	42,816 +9,941	+30%	+$510K	0.07%	193
2020 Q1	$1.56M	Hold	32,875	–	–	0.05%	200
2019 Q4	$1.93M	Hold	32,875	–	–	0.05%	198
2019 Q3	$1.75M	Buy	32,875 +5,456	+20%	+$281K	0.05%	198
2019 Q2	$1.37M	Hold	27,419	–	–	0.04%	213
2019 Q1	$1.43M	Buy	27,419 +133	+0.5%	+$6.65K	0.04%	215
2018 Q4	$1.3M	Buy	27,286 +406	+2%	+$20K	0.04%	209
2018 Q3	$1.35M	Buy	+26,880	New	+$1.37M	0.03%	217

Other funds holding GSK

KFP

Keystone Financial Planning Cleveland, Ohio $404M AUM 16.77% 1-Year Est. Return

Bonness Enterprises Washington, District of Columbia $307M AUM 22.88% 1-Year Est. Return

FFA

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

Parrish Capital Kennesaw, Georgia $103M AUM 35.11% 1-Year Est. Return

IRC

Investors Research Corp Atlanta, Georgia $569M AUM 15.41% 1-Year Est. Return

BCM

Boltwood Capital Management Walnut Creek, California $443M AUM 17.72% 1-Year Est. Return

VCM

Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return

CPBTD

Central Pacific Bank - Trust Division Honolulu, Hawaii $952M AUM 25.15% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

Rockland Trust Hanover, Massachusetts $2.61B AUM 14.26% 1-Year Est. Return

Moody National Bank Trust Division's GSK Position: Q3 2026 in Review

Moody National Bank Trust Division increased its GSK (GSK) stake by 0.51% in Q3 2026, buying an estimated $2.65K and bringing the position to 10,279 shares worth $495K. The position accounts for 0.04% of the portfolio, ranked #347.

Moody National Bank Trust Division first reported a position in GSK in Q3 2018 and has held it in 32 quarters since. The position peaked at $2.21M in Q2 2021. 33 funds tracked by Wall St. Rank hold GSK as of Q3 2026.

Moody National Bank Trust Division held 10,279 shares of GSK worth $495K as of Q3 2026.
Moody National Bank Trust Division bought 52 GSK shares in Q3 2026, an estimated $2.65K.
GSK made up 0.04% of Moody National Bank Trust Division's portfolio in Q3 2026, its #347 holding.
Moody National Bank Trust Division first reported a position in GSK in Q3 2018 and has held it in 32 quarters since.
Moody National Bank Trust Division's GSK position peaked at $2.21M in Q2 2021.
33 funds tracked by Wall St. Rank held GSK as of Q3 2026.

Based on Moody National Bank Trust Division's 13F filing for Q3 2026, filed 6 Oct 2026.